These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 1933339)

  • 21. Cholinergic activation of the electrocorticogram: an amygdaloid activating system.
    Dringenberg HC; Vanderwolf CH
    Exp Brain Res; 1996 Mar; 108(2):285-96. PubMed ID: 8815036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioral effects of anti-muscarinic, anti-serotonergic, and anti-NMDA treatments: hippocampal and neocortical slow wave electrophysiology predict the effects on grooming in the rat.
    Robertson BJ; Boon F; Cain DP; Vanderwolf CH
    Brain Res; 1999 Aug; 838(1-2):234-40. PubMed ID: 10446340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonergic involvement in phencyclidine-induced behaviors.
    Nabeshima T; Yamaguchi K; Hiramatsu M; Amano M; Furukawa H; Kameyama T
    Pharmacol Biochem Behav; 1984 Sep; 21(3):401-8. PubMed ID: 6208563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sparing of two types of hippocampal rhythmical slow activity (RSA, theta) in adult rats decorticated neonatally.
    Whishaw IQ; Dyck R; Kolb B
    Brain Res Bull; 1991 Mar; 26(3):425-7. PubMed ID: 2049610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rats and marmosets respond differently to serotonin agonists and antagonists.
    Campos MF; Rodrigues F das C
    Psychopharmacology (Berl); 1987; 92(4):478-83. PubMed ID: 3114802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of phencyclidine-induced dopamine-dependent behaviors in rats after pretreatments with serotonin-depletors.
    Yamaguchi K; Nabeshima T; Kameyama T
    J Pharmacobiodyn; 1986 May; 9(5):479-89. PubMed ID: 2945001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The contribution of tryptamine to the behavioural effects of l-Tryptophan in tranylcypromine-treated rats.
    Marsden CA; Curzon G
    Psychopharmacology (Berl); 1978 Apr; 57(1):71-6. PubMed ID: 149328
    [No Abstract]   [Full Text] [Related]  

  • 28. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
    Sagi Y; Driguès N; Youdim MB
    Br J Pharmacol; 2005 Oct; 146(4):553-60. PubMed ID: 16086033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological evidence that stimulation of central serotonergic pathways increases renin secretion.
    Zimmermann H; Ganong WF
    Neuroendocrinology; 1980; 30(2):101-7, 109. PubMed ID: 6986577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of serotonergic and antiserotonergic drugs on the flexor reflex of spinal rat: a proposed model to evaluate the action on the central serotonin receptor.
    Maj J; Palider W; Baran L
    J Neural Transm; 1976; 38(2):131-47. PubMed ID: 1083896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reserpine abolishes movement-correlated atropine-resistant neocortical low voltage fast activity.
    Vanderwolf CH; Pappas BA
    Brain Res; 1980 Nov; 202(1):79-94. PubMed ID: 7427747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations.
    Pranzatelli MR; Snodgrass SR
    Brain Res; 1986 Jan; 364(1):67-76. PubMed ID: 3484993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotyped hyperactivity in rats treated with tranylcypromine and specific inhibitors of 5-HT reuptake.
    Holman RB; Seagraves E; Elliott GR; Barchas JD
    Behav Biol; 1976 Apr; 16(4):507-14. PubMed ID: 134688
    [No Abstract]   [Full Text] [Related]  

  • 34. Serotonergic and antiserotonergic influences on amphetamine-induced stereotyped behavior.
    Weiner WJ; Goetz C; Westheimer R; Klawans HL
    J Neurol Sci; 1973 Dec; 20(4):373-9. PubMed ID: 4359068
    [No Abstract]   [Full Text] [Related]  

  • 35. Some behavioural interactions between 5-hydroxytryptamine and dopamine.
    Curzon G
    Adv Exp Med Biol; 1981; 133():563-84. PubMed ID: 6459008
    [No Abstract]   [Full Text] [Related]  

  • 36. A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists.
    Green AR; Hall JE; Rees AR
    Br J Pharmacol; 1981 Jul; 73(3):703-19. PubMed ID: 6166345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone.
    Green AR; O'Shaughnessy K; Hammond M; Schächter M; Grahame-Smith DG
    Neuropharmacology; 1983 May; 22(5):573-8. PubMed ID: 6603593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents.
    Simansky KJ; Schechter LE
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1073-81. PubMed ID: 3144595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Responses of developing rats to L-tryptophan plus an MAOI-I. Monitoring changes in behaviour, brain 5-HT and tryptophan.
    Atterwill CK; Green AR
    Neuropharmacology; 1980 Apr; 19(4):325-35. PubMed ID: 7383278
    [No Abstract]   [Full Text] [Related]  

  • 40. The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs.
    Yamamoto T; Ueki S
    Pharmacol Biochem Behav; 1981 Jan; 14(1):89-95. PubMed ID: 6258178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.